Biopharmaceutical Innovation
Engineering the next generation of androgenic hair growth therapeutics.
Developed in partnership with leading dermatological research institutions, our SP1-7 Folliculin Complex™ targets dormant follicular units at the cellular level — delivering clinically measurable beard density in as few as 8 weeks.
The Science
Dormant follicles aren't dead. They're waiting for the right signal.
The SP1-7 Folliculin Complex™ is a proprietary bioactive peptide formulation engineered to reactivate the Wnt/β-catenin signaling pathway in vellus hair follicles, stimulating transition into terminal anagen growth phase. Unlike conventional topical DHT blockers, our mechanism works upstream — restoring the cellular environment for sustained, natural follicular cycling.
Targets Wnt/β-catenin and FGF-7 pathways that govern follicle cycling and anagen re-entry in dormant dermal papilla cells.
Our lipid nanoparticle carrier system achieves 3.8× greater dermal penetration than standard emulsion-based formulas.
No measurable serum absorption of active compounds detected across all Phase I cohorts. No hormonal pathway interference.
Our Portfolio
From preclinical support serums to our flagship therapeutic — the SP1-7 suite is built around measurable outcomes.
A preparatory microbiome-balancing serum that primes the follicular environment ahead of SP1-7 therapeutic application. Clinically formulated with prebiotic beta-glucan and niacinamide.
Our core innovation. A physician-grade topical therapeutic delivering our patented bioactive peptide complex via advanced lipid nanoparticle carrier system for maximum follicular uptake.
Designed for post-growth consolidation. Sustains anagen phase duration and prevents follicular miniaturization using a proprietary prostaglandin E2 analogue and antioxidant complex.
Clinical Evidence
Our Phase II double-blind, placebo-controlled trial across 847 male subjects ages 21–54.
Conducted at five independent dermatology research centers, our trial protocol follows ICH E6(R2) Good Clinical Practice guidelines. Primary endpoints measure terminal follicle count per cm² using dermoscopy imaging at weeks 8, 16, and 24.
From Our Participants
By week ten, I had visible coverage in areas that had been bare for over a decade. The process was simple, the team was professional, and the results were genuinely beyond what I expected.
I've tried every topical on the market. Nothing came close to what the SP1-7 serum did in sixteen weeks. The density and uniformity of growth was unlike anything I've experienced.
As a dermatologist observing this trial, the histological evidence of follicular reactivation was compelling. The SP1-7 mechanism addresses root-cause biology rather than surface symptoms.
Early Access
Join the SP1-7 Labs early access registry to receive trial enrollment updates, research publications, and priority access when FolliPrime™ enters commercial availability.
No spam. No sharing. Unsubscribe at any time. This site is for training purposes only.